MARKET

CARA

CARA

Cara
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.13
+0.26
+2.19%
Opening 15:32 07/28 EDT
OPEN
11.91
PREV CLOSE
11.87
HIGH
12.25
LOW
11.91
VOLUME
234.47K
TURNOVER
--
52 WEEK HIGH
29.65
52 WEEK LOW
11.58
MARKET CAP
607.13M
P/E (TTM)
65.50
1D
5D
1M
3M
1Y
5Y
AusCann, Flower One, Item 9 Labs & MariMed Among Top Cannabis Stock Movers On July 23, 2021
GAINERS: Cann Gr (OTC: CNGGF) shares closed up 20.58% at $0.35
Benzinga · 4d ago
Bullish Sentiment Pumps Up Cannabis Stocks: Tilray, Sundial, Aurora & GrowGen Among Top Cannabis Movers For July 20, 2021
GAINERS: Empower Clinics (OTC: EPWCF) shares closed up 18.43% at $0.39
Benzinga · 07/20 21:58
General Cannabis, MariMed & Urban-Gro Among Top Cannabis Stock Movers On July 13, 2021
GAINERS: CURE Pharmaceutical Hldg (OTC: CURR) shares closed up 17.02% at $0.55
Benzinga · 07/13 23:40
15 Most Valuable Weed Companies in the World
In this article we will take a look at the 15 most valuable weed companies in the world. You can skip our detailed analysis of the weed industry, and go directly to the 5 Most Valuable Weed Companies in the World. Weed is a psychoactive drug developed from...
Insider Monkey · 07/12 14:26
A Complete List Of NYSE And NASDAQ-Listed Cannabis Companies (Updated)
As the cannabis industry keeps pushing forward, more companies are moving to list their stock on a major U.S. exchange like the NYSE or NASDAQ. The club, however, remains relatively small.
Benzinga · 07/02 18:22
Cara Therapeutics Insights: Return On Capital Employed
During Q1, Cara Therapeutics (NASDAQ:CARA) brought in sales totaling $1.94 million. However, earnings decreased 130.09%, resulting in a loss of $23.56 million. Cara Therapeutics reached earnings of $78.29 million and sales of $112.09 million in Q4.
Benzinga · 06/22 14:18
Cara Therapeutics Granted U.S. Patent Titled 'Oral formulations of kappa opioid receptor agonists'
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=6620&f=G&l=50&d=PTXT&p=133&S1=20210615&OS=20210615&RS=20210615
Benzinga · 06/15 19:18
BRIEF-Swk Holdings' Subsidiary, Enteris Biopharma, Receives $10 Million Milestone Payment From Cara Therapeutics
reuters.com · 06/11 12:44
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CARA. Analyze the recent business situations of Cara through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CARA stock price target is 27.63 with a high estimate of 33.00 and a low estimate of 17.00.
EPS
Institutional Holdings
Institutions: 237
Institutional Holdings: 33.25M
% Owned: 66.44%
Shares Outstanding: 50.05M
TypeInstitutionsShares
Increased
46
2.01M
New
34
1.03M
Decreased
51
2.68M
Sold Out
17
611.58K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.66%
Pharmaceuticals & Medical Research
+2.13%
Key Executives
President/Chief Executive Officer/Director
Derek Chalmers
Chief Financial Officer
Thomas Reilly
Senior Vice President/Chief Scientific Officer
Frederique Menzaghi
Chief Compliance Officer/General Counsel/Secretary
Scott Terrillion
Other
Joana Goncalves
Lead Director/Independent Director
Martin Vogelbaum
Independent Director
Harrison Bains
Independent Director
Jeffrey Ives
Independent Director
Christopher Posner
Independent Director
Susan Shiff
No Data
About CARA
Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body's peripheral nervous system. The Company operates through the activities related to the discovery and development of therapeutics to treat serious medical conditions, including pain and pruritus. Its product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845 for acute and chronic pain, and CR701 for neuropathic and inflammatory pain. I.V. CR845 is an injectable version of peripheral kappa opioid receptor agonist, which is intended for the treatment of acute pain in an acute care setting. CR845 has exhibited anti-pruritic, or anti-itch, potency in standard preclinical models.

Webull offers kinds of Cara Therapeutics Inc stock information, including NASDAQ:CARA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CARA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CARA stock methods without spending real money on the virtual paper trading platform.